Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors

…, EF Brigham, D Chian, M Franzini, E Goldbach…

Index: Garofalo, Albert W.; Adler, Marc; Aubele, Danielle L.; Brigham, Elizabeth F.; Chian, David; Franzini, Maurizio; Goldbach, Erich; Kwong, Grace T.; Motter, Ruth; Probst, Gary D.; Quinn, Kevin P.; Ruslim, Lany; Sham, Hing L.; Tam, Danny; Tanaka, Pearl; Truong, Anh P.; Ye, Xiaocong M.; Ren, Zhao Bioorganic and Medicinal Chemistry Letters, 2013 , vol. 23, # 7 p. 1974 - 1977

Full Text: HTML

Citation Number: 16

Abstract

Mutations in leucine-rich repeat kinase 2 (LRRK2) are associated with familial Parkinson's disease (PD). The kinase activity of this complex protein is increased by pathogenic mutations. Inhibition of LRRK2 kinase activity has therefore emerged as a promising approach for the treatment of PD. Herein we report our findings on a series of 4-alkylamino-7- aryl-3-cyanoquinolines that exhibit kinase inhibitory activity against both wild type and ...